Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.

@article{Bertram2007CostsAB,
  title={Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.},
  author={Melanie Y. Bertram and Stephen S. Lim and Angela L Wallace and Theo Vos},
  journal={Tobacco control},
  year={2007},
  volume={16 4},
  pages={255-60}
}
BACKGROUND Tobacco smoking is the leading preventable cause of morbidity and mortality in Australia and other developed countries. Of the pharmacological aids that are available for smoking cessation, bupropion (Zyban SR) is eligible for public reimbursement on the Australian Pharmaceutical Benefits Scheme (PBS), whereas nicotine replacement therapy (NRT) is not. Information on the cost-effectiveness and financial impact of public reimbursement of these strategies can better inform debate about… CONTINUE READING
13 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…